Population Pharmacokinetics of Docetaxel, Paclitaxel, Doxorubicin and Epirubicin in Pregnant Women with Cancer: A Study from the International Network of Cancer, Infertility and Pregnancy (INCIP)

Autor: Ingrid A. Boere, Robert Fruscio, Jos H. Beijnen, Petronella O. Witteveen, Carolien P. Schröder, Rebecca C. Painter, Alwin D. R. Huitema, Petronella B. Ottevanger, Frédéric Amant, Julie M Janssen, Vit Drochytek, Thomas P. C. Dorlo, Michael J. Halaska, Ruud L.M. Bekkers, Kristel Van Calsteren

Publikováno v: Clinical Pharmacokinetics, 60, 6, pp. 775-784
Clinical Pharmacokinetics
Clinical Pharmacokinetics, 60, 775-784
Clinical Pharmacokinetics. Springer International Publishing AG
Clinical pharmacokinetics, 60(6), 775-784. Adis International Ltd
Clinical Pharmacokinetics, 60(6), 775-784. Adis
Clinical Pharmacokinetics, 60(6), 775-784. Adis International Ltd

BACKGROUND: Based on reassuring short-term foetal and maternal safety data, there is an increasing trend to administer chemotherapy during the second and third trimesters of pregnancy. The pharmacokinetics (PK) of drugs might change as a result of se

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9084c1fbb357789b249834c0a9474a42
https://repository.ubn.ru.nl/handle/2066/235476